Clearance of Continuously Infused 5-Fluorouracil in Adults Having Lung or Gastrointestinal Carcinoma with or without Hepatic Metastases
Authors:
- Ronald A. FloydRFRonald A. Floyd
- Cecil L. HornbeckCHCecil L. Hornbeck
- John E. ByfieldJBJohn E. Byfield
- John C. GriffithsJGJohn C. Griffiths
- Sallie S. FrankelSFSallie S. Frankel
- 1 September 1982
- journal article
- research article
- Published by SAGE Publications in Drug Intelligence & Clinical Pharmacy
- Vol. 16 (9) , 665-667
Abstract
The steady-state apparent total body clearances (TBC) of continuously infused 5-fluorouracil (5-FU) were determined in 16 adult male patients who were receiving combined 5-FU-radiation therapy. Seven patients (group A) had Stage III adenocarcinoma or epidermoid lung carcinomas; none had known metastases. Five patients had gastrointestinal carcinomas (group B), without known hepatic metastases. Four had gastrointestinal carcinomas with evidence of hepatic metastases (group C). TBCs were calculated from infusion rates and serum 5-FU concentration data. The means (standard errors) of the TBCs were: Group A, 4.49 (0.53); group B, 6.51 (0.53); group C, 2.96 (0.91) L/kg/h. The difference among the means was found to be significant ( p 〈 0.002) by one-way ANOVA. Differences among the groups were then examined using 95 percent confidence intervals: Group A was not different from group B or group C; however, groups B and C differed from each other. Patients with hepatic metastases have 5-FU TBCs about half that of those found in patients without hepatic involvement. Clinically, patients in group C attained the higher serum 5-FU concentrations known to be radiosensitizing more frequently than patients in the other two groups; differences in toxicity were not evident. This suggests that administration of an agent that can compete with 5-FU for hepatic metabolism to patients with rapid clearance might improve the therapeutic efficacy of 5-FU.This publication has 8 references indexed in Scilit:
- Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X raysInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1982
- Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routesClinical Pharmacology & Therapeutics, 1980
- An overview of thymidineCancer, 1980
- Infusional 5-fluorouracil and x-ray therapy for non-resectable esophageal cancerCancer, 1980
- Plasma levels of 5‐fluorouracil after oral and intravenous administration in cancer patients.British Journal of Clinical Pharmacology, 1979
- Kinetics and Mechanisms of Drug Action on Microorganisms XXIII: Microbial Kinetic Assay for Fluorouracil in Biological Fluids and Its Application to Human PharmacokineticsJournal of Pharmaceutical Sciences, 1977
- Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinomaCancer, 1975
- The metabolism of uracil‐2‐14C and the granulocyte response to endotoxin as indicators of the toxicity produced in patients receiving 5‐fluorouracilClinical Pharmacology & Therapeutics, 1967